G35.C1

Clinical Causes: Autoimmune response: The immune system mistakenly attacks the protective covering (myelin) of nerve fibers in the central nervous system. Genetic factors: Certain genetic predispositions can increase the risk of developing MS. Environmental influences: Factors such as vitamin D deficiency, smoking, and exposure to certain infections may contribute to disease onset and progression. Previous relapsing-remitting MS: Transition from relapsing-remitting MS to secondary progressive MS indicates a change in disease activity, potentially driven by ongoing inflammation and neurodegeneration.

Key Symptoms: Gradual worsening of muscle strength, often affecting limbs and gait. Increased fatigue and reduced stamina. Neurocognitive changes, including problems with memory, concentration, and information processing. Spasticity or muscle stiffness. Difficulties with coordination and balance. Sensory disturbances such as numbness, tingling, or burning sensations. Bladder and bowel dysfunction. Visual disturbances, including blurred vision or optic neuritis. Persistent neurological symptoms that worsen over time, despite the absence of relapses.

Diagnosis Path: Diagnosing active secondary progressive MS involves a combination of medical history, neurological examination, and diagnostic tests. Key elements include: - Magnetic resonance imaging (MRI): Detects active inflammation through the presence of new or enhancing lesions in the brain and spinal cord. - Cerebrospinal fluid (CSF) analysis: May reveal inflammatory markers, oligoclonal bands, and other signs of ongoing immune activity. - Clinical assessments: Monitoring of neurological function over time to observe progression and activity. - Exclusion of other conditions that could mimic MS symptoms. Early and accurate diagnosis is essential for appropriate management. The presence of evidence indicating active inflammation, such as new MRI lesions or clinical relapses, supports the diagnosis of active disease, influencing treatment decisions.

Treatment Protocols: Managing active secondary progressive MS aims to not only slow disease progression but also reduce inflammation and manage symptoms. Treatment options include: - Disease-modifying therapies (DMTs): Medications like monoclonal antibodies (e.g., ocrelizumab) and other immunomodulators that specifically target inflammatory activity. - Corticosteroids: Used during relapses or periods of increased disease activity to reduce inflammation. - Symptomatic treatments: Including physical therapy, spasticity management, bladder and bowel control, and pain management. - Lifestyle modifications: Regular exercise, healthy diet, and smoking cessation can support overall health. - Clinical trials: Participation in emerging research studies may provide access to novel therapies. Ongoing monitoring and regularly adjusting treatment plans are vital for managing active SPMS effectively.